natgillin/translations-raw huggingface dataset:
The ferritic stainless steel of any of claims 1-7 wherein nickel is present in an amount of 0.40 or less percent by weight. 
Feritni nehrđajući čelik u skladu s bilo kojm od patentnih zahtjeva 1-7, naznačen time što je nikal prisutan u količini od 0,40 ili manje postotaka, težinski.
the polymorph exhibits an X-ray powder diffraction pattern having one or more characteristic peaks expressed in degrees 2-theta at about 3.9 +/- 0.3 degrees, about 17.5 +/- 0.3 degrees, and about 22.0 +/- 0.3 degrees 2-theta; or 
Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima one ili more karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 17.5 +/- 0.3 stupnjeva, te oko 22.0 +/- 0.3 stupnjeva 2-theta.
the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 3.9 +/- 0.3 degrees, about 17.5 +/- 0.3 degrees, and about 22.0 +/- 0.3 degrees 2-theta; or 
Polimorf prema bilo kojem od zahtjeva 8-9, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima karakteristične vrškove izražene u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 17.5 +/- 0.3 stupnjeva, te oko 22.0 +/- 0.3 stupnjeva 2-theta.
or Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7 membered heterocycloalkyl group, which is optionally substituted with -OH or C1-3 alkyl; and 
ili Rc1 i Rd1 zajedno sa atomom N za koji su vezani može obrazovati 4-, 5-, 6- ili 7-članu heterocikloalkil grupu koja dalje može biti supstituirana sa -OH ili C1-3 alkil grupom;
A method according to claim 1, characterized in that the framework (2, 22) of the module (1, 21) is constructed to extend in vertical direction to a plurality of ship deck platforms, the module is fitted with the equipment units (8, 9, 10, 25) of several different deck platforms, and the module's framework is formed with lightened cover structures (4, 5, 24), which cover structures settle in flushness with the ship decks once the module has been set in its position. 
Postupak prema zahtjevu 1, naznačen time da je okvir (2, 22) modula (1, 21) konstruiran tako da se proteže u okomitom smjeru prema više platformi brodske palube, modul je opremljen jedinicama za opremanje (8, 9, 10, 25) nekoliko različitih platformi palube, i okvir modula formiran je lakim pokrovnim strukturama (4, 5, 24), koje pokrovne strukture se smještaju jedna do druge u ravnini s brodskim palubama nakon što je modul postavljen na svoj položaj.
A method according to claim 2, characterized in that the cover structures (4, 5, 24) of the fixedly mounted module (1, 21) are secured to a ship's structure substantially in line with the ship decks by way of protrusions extending out of the ship's hull structure. 
Postupak prema zahtjevu 2, naznačen time da su pokrovne strukture (4, 5, 24) fiksno montiranog modula (1, 21) fiksirane za brodsku konstrukciju značajno u ravnini sa brodskim palubama putem izbočenja koja strše van iz konstrukcije trupa broda.
A method according to any of claims 1-5, characterized in that the components (3, 6, 7, 11, 16, 23, 26, 27) dismantled from the framework (2, 22) of the module (1, 21) are reused in the frameworks of new modules. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time da su komponente (3, 6, 7, 11, 16, 23, 26, 27) demontirane sa okvira (2, 22) modula (1, 21) ponovno upotrebljene u okvirima novih modula.
A module (1,21) according to claim 8, characterized in that the module (1, 21) has its cover structures (4, 5, 24) adapted to be supported by a ship's structure on protrusions extending from the ship's hull structure substantially in alignment with the ship decks. 
Modul (1,21) prema zahtjevu 8, naznačen time da modul (1, 21) ima pokrovne strukture (4, 5, 24) koje su prilagođene da budu poduprte konstrukcijom broda na izbočenjima koja se protežu iz konstrukcije brodskog trupa značajno u ravnini sa brodskim palubama.
The compound of claim 1 or 2, wherein R2 is NR6R7. 
Tvar iz patentnog zahtjeva 1 ili 2, pri čemu R2 predstavlja NR6R7.
The compound of claim 3, wherein R7 is OR14, wherein R14 is alkyl. 
Tvari iz patentnog zahtjeva 3, pri čemu R7 predstavlja OR14, gdje je R14 alkil.
A compound having the formula VIIa: or a tautomer, enantiomer or salt, preferably a pharmaceutically acceptable salt thereof, wherein: 
Tvar koja ima formulu VIIa: [image] ili njen tautomer, enantiomer ili sol, poželjno njena farmaceutski prihvatljiva sol, pri čemu:
A compound of claim 1 or 7 being selected from the group consisting of: 104 105 
Tvar iz patentnog zahtjeva 1 ili 7 odabrana je iz grupe koja se sastoji od:
The compound according to claim 9, selected from the group consisting of: 
Tvar u skladu s patentnim zahtjevom 9, odabrana iz grupe koja se sastoji od:
A kit for treating cancer or an allergic disease, comprising: 
Komplet za liječenje raka ili alergijske bolesti, obuhvaća:
a pharmaceutical composition comprising a compound of any of claims 1-11 or a tautomer, enantiomer or salt, preferably a pharmaceutically acceptable salt thereof; and 
farmaceutski sastav koji sadrži tvar iz bilo kojeg od patentnih zahtjeva 1-11 ili njen tautomer, enantiomer ili sol, poželjno njenu farmaceutski prihvatljivu sol; i
optionally instructions for use. 
opcionalno upute za uporabu.
A pharmaceutical composition, which comprises a compound of any of claims 1-11 or a tautomer, enantiomer or salt, preferably a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, koji sadrži tvar iz bilo kojeg od patentnih zahtjeva 1-11 ili njen tautomer, enantiomer ili sol, poželjno njenu farmaceutski prihvatljivu sol zajedno s farmaceutski prihvatljivim diluentom ili nosačem.
A compound of any of claims 1-11 or a tautomer, enantiomer or salt, preferably a pharmaceutically acceptable salt thereof for use in treating cancer, wherein said cancer is selected from biliary tract cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasms, leukemia, lymphoma, liver cancer, lung cancer, melanoma, neuroblastomas, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, sarcomas, skin cancer, testicular cancer, thyroid cancer, other carcinomas and sarcomas. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-11 ili njen tautomer, enantiomer ili sol, poželjno njena farmaceutski prihvatljiva sol za uporabu u liječenju raka, pri čemu je navedeni rak odabran između karcinoma žučnih puteva, raka mozga, karcinoma dojke, karcinoma cerviksa, koriokarcinoma, karcinoma kolona, karcinoma endometrija, karcinoma jednjaka, karcinoma želuca, intraepitelnih neoplazmi, leukemije, limfoma, karcinoma jetre, karcinoma pluća, melanoma, neuroblastoma, karcinoma usne šupljine, karcinoma jajnika, karcinoma gušterače, karcinoma prostate, karcinoma rektuma, karcinoma bubrega, sarkoma, raka kože, karcinoma testisa, karcinoma štitnjače, drugih karcinoma i sarkoma.
A compound of any of claims 1-11 or a tautomer, enantiomer or salt, preferably a pharmaceutically acceptable salt thereof for use in modulating a patient's immune system. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-11 ili njen tautomer, enantiomer ili sol, poželjno njena farmaceutski prihvatljiva sol za uporabu u moduliranju imunološkog sustava pacijenta.
A pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3S,3S') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin converting enzyme inhibitors selected from enalapril, captopril, ramipril, and quinapril and angiotensin II receptor type 1 antagonists selected from losartan, candesartan, valsartan and olmesartan. 
Farmaceutski sastav sadrži, u najmanje jednom farmaceutski prihvatljivom pomagalu ili nosaču, kombinaciju (3S,3S') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) ili njene farmaceutski prihvatljive soli ili solvata i drugog aktivnog sastojka odabranog iz grupe koje se sastoji od inhibitora angiotenzin konvertirajućeg enzima odabranih između enalaprila, kaptoprila, ramiprila i kvinaprila i antagonista receptora angiotenzina II tipa 1 odabranih između losartana, kandesartana, valsartana i olmesartana.
The pharmaceutical composition according to Claim 1, wherein the angiotensin converting enzyme inhibitor is enalapril. 
Farmaceutski sastav u skladu s patentnim zahtjevom 1, pri čemu je inhibitor angiotenzin konvertirajućeg enzima enalapril.
The pharmaceutical composition according to Claim 1, wherein the angiotensin II receptor type 1 antagonist is valsartan. 
Farmaceutski sastav u skladu s patentnim zahtjevom 1, pri čemu je antagonist receptora angiotenzina II tipa 1 valsartan.
The pharmaceutical composition according to Claim 1, wherein the angiotensin II receptor type 1 antagonist is losartan. 
Farmaceutski sastav u skladu s patentnim zahtjevom 1, pri čemu je antagonist receptora angiotenzina II tipa 1 losartan.
The pharmaceutical composition according to anyone of the preceding claims, wherein the pharmaceutically acceptable support or vehicle is suitable for an oral administration. 
Farmaceutski sastav u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je farmaceutski prihvatljivo pomagalo ili nosač pogodno za oralnu primjenu.
The pharmaceutical composition as defined in anyone of the preceding claims, for a use in the treatment of arterial hypertension or indirectly or directly related diseases, especially heart failure. 
Farmaceutski sastav u skladu s bilo kojim od prethodnih patentnih zahtjeva, za uporabu u liječenju arterijske hipertenzije ili neizravno ili izravno povezanih bolesti, posebno zatajenja srca.
The pharmaceutical composition according to claim 6 or 7, wherein both active ingredients are coadministered, preferably simultaneously coadministered. 
Farmaceutski sastav u skladu s patentnim zahtjevom 6 ili 7, pri čemu se oba aktivna sastojka daju zajedno, poželjno istovremeno zajedno.
A kit comprising a composition containing (3S,3S') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second composition containing a second active ingredient selected from the group consisting of angiotensin converting enzyme inhibitors selected from enalapril, captopril, ramipril, and quinapril and angiotensin II receptor type I antagonists selected from losartan, candesartan, valsartan and olmesartan, for a simultaneous, separate or sequential administration, preferably for simultaneous administration. 
Komplet obuhvaća sastav koji sadrži (3S,3S') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonsku kiselinu) ili njenu farmaceutski prihvatljivu soli ili solvat i drugi sastav koji sadrži drugi aktivni sastojak odabran iz grupe koje se sastoji od inhibitora angiotenzin konvertirajućeg enzima odabranih između enalaprila, kaptoprila, ramiprila i kvinaprila i antagonista receptora angiotenzina II tipa 1 odabranih između losartana, kandesartana, valsartana i olmesartana, za istovremenu, zasebnu ili primjenu u slijedu, poželjno za istovremenu primjenu.
A bifunctional molecule comprising a polypeptide binding partner specific for a given pMHC epitope, and an immune effector polypeptide, the N-terminus of the pMHC binding partner being linked to the C-terminus of the immune effector polypeptide, PROVIDED THAT the said polypeptide binding partner is not a T-cell receptor comprising the alpha chain SEQ ID No: 7 and the beta chain SEQ ID No: 9 wherein the pMHC binding partner is a heterodimeric aβ TCR polypeptide pair, or a single chain aβ TCR polypeptide, and the N-terminus of the a or β chain of the heterodimeric TCR polypeptide pair, or the N-terminus of the scTCR polypeptide, is linked to a C-terminal amino acid of the immune effector polypeptide and wherein the immune effector polypeptide is an antibody which specifically binds to an antigen presented by a T-cell. 
Bifunkcionalna molekula koja sadrži polipeptidni vezivajući partner specifičan za navedeni pMHC epitop, i imuni efektorni polipeptid, pri čemu je N-terminus pMHC vezivajućeg partnera vezan za C-terminus imunog efektornog polipeptida, UZ UVJET DA navedeni polipeptidni vezivajući partner nije T-stanični receptor koji sadrži alfa lanac SEQ ID No: 7 i beta lanac SEQ ID No: 9, pri čemu pMHC vezivajući partner je heterodimerni aβ TCR polipeptidni par, ili jednolančani aβ TCR polipeptid, i N-terminus a ili β lanca heterodimernog TCR polipeptidnog para ili N-terminus scTCR polipeptida, je vezan sa C-terminalnom aminokiselinom imunog efektornog polipeptida i pri čemu imuni efektorni polipeptid je antitijelo koje se specifično veže za antigen predstavljen preko T-stanice.
Frustoconical- or truncated pyramid-shaped support structure formed by several precast concrete panels, characterized in that it has no horizontal joints between panels since all of them have the total height of said structure, all the panels (1) having the same dimensions, at least two of these panels being located contiguous to one another to form a support structure having a closed section and being designed such that the vertical joints (2) between contiguous panels have a larger opening in the upper portion than in the lower portion, which allows obtaining different section widths in the upper portion of the mentioned structure by adjusting said opening more or less. 
Nosiva struktura u obliku krnjeg stošca - ili u obliku krnje piramide formirana od nekoliko predgotovljenih betonskih panela, naznačena time da između panela nema vodoravne spojeve jer su svi redom imaju ukupnu visinu navedene strukture, svi paneli (1) ima iste dimenzije, najmanje dva od ovih panela se nalaze susjedni jedan s drugim da formiraju potpornu strukturu koja ima zatvoren profil koji je dizajniran tako da vertikalne spojnice (2) između susjednih panela imaju veći otvor u gornjem dijelu nego u donjem dijelu, koji omogućuje dobivanje različitih širina presjeka u gornjem dijelu navedene strukture podešavanjem navedenog otvora ili više ili manje.
Frustoconical- or truncated pyramid-shaped support structure formed by several precast concrete panels according to the preceding claim, characterized in that the first panel that will be assembled on-site incorporates a platform (3) having fixed dimensions and the shape of which is concentric to the final section to be obtained, being anchored at a certain height of the upper portion of this panel, serving as a guide and support for the remaining panels and allowing the adjustment of section width in the upper portion of the tower by simply changing the anchoring height of said platform (3). 
Nosiva struktura u obliku krnjeg stošca - ili u obliku krnje piramide formirana od nekoliko predgotovljenih betonskih panela prema prethodnom zahtjevu, naznačena time da je prvi panel koji će biti sklopljen na licu mjesta uključuje platformu (3) koja ima fiksne dimenzije i oblik koji je koncentričan u odnosu na dobiveni završni profil, i koja je usidrena na određenoj visini gornjeg dijela ovog panela, koji služi kao vodilica i nosač za preostale panele i koji omogućava prilagodbu širine profila u gornjem dijelu tornja jednostavnom promjenom visine sidrenja navedene platforme (3).
Frustoconical- or truncated pyramid-shaped support structure formed by several precast concrete panels according to the preceding claims, characterized in that the panels (1) are pre-tensioned or post-tensioned internally, i.e., inside the concrete section, before the placement thereof, not requiring any additional tensioning cable on-site. 
Nosiva struktura u obliku krnjeg stošca - ili u obliku krnje piramide formirana od nekoliko predgotovljenih betonskih panela prema prethodnim zahtjevima, naznačena time da su paneli (1) unaprijed zategnuti ili interno naknadno-zategnuti, tj. unutar betonskog dijela, prije njegovog stavljanja, što na licu mjesta ne zahtijeva nikakve dodatne kabel za zatezanje.
Frustoconical- or truncated pyramid-shaped support structure formed by several precast concrete panels according to all the preceding claims, characterized in that the panels (1) have a thickening in the upper portion having a thickness at least twice the minimum thickness of the panel on which a steel tower is coupled by means of a hollow cylinder-shaped transition part of a mixed steel-concrete composition, in which its height is less than half its outer diameter and its wall thickness is at least twice the minimum thickness of the precast panels forming the support structure. 
Nosiva struktura u obliku krnjeg stošca - ili u obliku krnje piramide formirana od nekoliko predgotovljenih betonskih panela prema svim prethodnim zahtjevima, naznačena time da paneli (1) u gornjem dijelu imaju zadebljanje koje ima debljinu najmanje dva puta minimalne debljina panela na koji je spojen čelični toranj pomoću prijelaznog dijela u obliku šupljeg cilindra koji je mješovitog sastava čelik-beton, čija visina je manja od polovine svog vanjskog promjera a debljina njegove stjenke je najmanje dva puta minimalne debljina predgotovljenih panela koji tvore potpornu strukturu.
wherein step a) comprises mixing said cell suspension with lysis solution in a high shear, in-line mixer; 
pri čemu korak a) obuhvaća miješanje navedene otopine stanica s otopinom za liziranje u velikom protoku, u linijskom miješalu;
The method of any one of claims 1 to 2, wherein the producing step comprises contacting the cell suspension with the lysis solution in a mixer over a duration of from about 1 minutes to about 20 minutes or from about 4 minutes to about 8 minutes or about 5 minutes. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 2, pri čemu korak proizvodnje obuhvaća dovođenje u dodir suspenzije stanica s lizirajućom otopinom u miješalu u trajanju od otprilike 1 minute do otprilike 20 minuta ili od otprilike 4 minute do otprilike 8 minuta ili otprilike 5 minuta.
The method of any one of claims 1 to 3 wherein said ion exchange is an anion exchange membrane. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 3, pri čemu je navedena ionska izmjena anionska izmjenjivačka membrana.
The method any one of claims 1 to 4, wherein step e) comprises performing hydrophobic interaction separation comprises butyl hydrophobic interaction chromatography in order to produce a hydrophobic interaction solution that is a butyl hydrophobic interaction chromatography solution eluate. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu korak e) obuhvaća izvođenje razdvajanja hidrofobnom interakcijom koje obuhvaća butilnu hidrofobnu interakcijsku kromatografiju zbog proizvodnje otopine hidrofobne interakcije koja je eluat otopine butilne hidrofobne interakcijske kromatografije.
assaying said polymyxin derivative for the ability to sensitize Gram-negative bacteria to an antibacterial agent; and 
ispitivanje tog derivata polimiksina na sposobnost pojačati osjetljivost gram-negativnih bakterija na antibakterijsko sredstvo; i
modifying a natural or synthetic polymyxin or octapeptin compound or a derivative thereof having 4 to 5 positively charged residues and a terminal moiety (D) comprising a total of 1 to 5 carbon atoms by replacing 1 to 2 of said residues by neutral residues, or by a covalent bond, or converting 1 to 2 of said residues into neutral residues in order to obtain a polymyxin derivative of formula (I) according to claim 1, having 3 positively charged residues and a terminal moiety (D) comprising a total of 1 to 5 carbon atoms; or 
modificiranje prirodnog ili sintetičkog spoja polimiksina ili oktapeptina ili njegovog derivata s 4 do 5 pozitivno nabijenih ostataka i terminalnom skupinom (D) s ukupno 1 do 5 atoma ugljika putem zamjene 1 do 2 tih ostataka neutralnim ostacima, ili kovalentnom vezom, ili pretvorbom 1 do 2 tih ostataka u neutralne ostatke radi dobivanja derivata polimiksina formule (I) prema zahtjevu 1, s 3 pozitivno nabijena ostatka i terminalnom skupinom (D) s ukupno 1 do 5 atoma ugljika; ili
modifying a natural or synthetic polymyxin or octapeptin compound or a derivative thereof having 4 to 6 positively charged residues and lacking the terminal moiety (D) by replacing 1 to 3 of said residues by neutral residues, or by a covalent bond, or converting 1 to 3 of said residues into neutral residues, and by introducing a terminal moiety (D) comprising a total of 1 to 5 carbon atoms, in order to obtain a polymyxin derivative of formula (I) according to claim 1, having 3 positively charged residues and a terminal moiety (D) comprising a total of 1 to 5 carbon atoms. 
modificiranje prirodnog ili sintetičkog spoja polimiksina ili oktapeptina ili njegovog derivata s 4 do 6 pozitivno nabijenih ostataka i bez terminalne skupine (D) putem zamjene 1 do 3 tih ostataka neutralnim ostacima, ili kovalentnom vezom, ili pretvorbom 1 do 3 tih ostataka u neutralne ostatke, i putem uvođenja terminalne skupine (D) s ukupno 1 do 5 atoma ugljika, radi dobivanja derivata polimiksina formule (I) prema zahtjevu 1, s 3 pozitivno nabijena ostatka i terminalnom skupinom (D) s ukupno 1 do 5 atoma ugljika.
The composition of claim 6, wherein the polypeptide comprises 23 repeating units derived from the C-terminal domain of toxin B of Clostridium difficile. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 3, pri čemu polipeptid sadrži 23 ponavljajuće jedinice izvedene iz C-terminalne domene toksina B iz Clostridium difficile.
The composition of claim 6, further comprising an adjuvant. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 6, nadalje sadrži adjuvans.
The protein according to any one of claims 1-8 or the nucleic acid of claim 9, for use in the treatment of diseases, wherein the formation of cartilage is desired but the formation of bone is undesirable. 
Varijanta proteina prema patentnom zahtjevu 1 ili nukleinska kiselina prema patentnom zahtjevu 2, za uporabu u liječenju bolesti, gdje je formiranje hrskavice poželjno, ali je formiranje kosti nepoželjno.
A nucleic acid encoding a variant protein according to claim 1. 
Nukleinska kiselina koja kodira varijantu proteina prema patentnom zahtjevu 1.
The variant protein according to claim 1 or the nucleic acid of claim 2, for use in the treatment of diseases, wherein the formation of cartilage is desired but the formation of bone is undesirable. 
Varijanta proteina prema patentnom zahtjevu 1 ili nukleinska kiselina prema patentnom zahtjevu 2, za uporabu u liječenju bolesti, gdje je formiranje hrskavice poželjno, ali je formiranje kosti nepoželjno.
A paraffin fraction consisting of 98.0-99.9% by weight C4-C12 i- and n-paraffins with 1:4 to 4:1 i/n mass ratio and 0.1-2.0% by weight C4-C10 carboxylic acid esters, wherein the boiling range of the paraffin fraction is 20-250°C. 
Frakcija parafina koja se u 98.0-99.9% težine sastoji od C4-C12 i- i n-parafina s omjerom mase i/n 1:4 do 4:1 i 0.1-2.0% težine C4-C10 estera karboksilnih kiselina, gdje je raspon vrelišta parafinske frakcije 20-250°C.
The use of the product according to claim 1 in internal combustion engines as fuel and/or fuel blend component. 
Uporaba proizvoda prema zahtjevu 1, u motorima s unutarnjim izgaranjem, kao goriva i/ili sastojka smjese goriva.
A method according to any one of claims 1 to 4, wherein said stem cells are intestinal, retina, brain, breast, hair follicle, stomach, liver, lung, pancreas, testis, heart or ovarian stem cells. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da matične stanice su matične stanice crijeva, mrežnice, mozga, dojke, folikula kose, želuca, jetre, pluća, gušterače, testisa, srca ili matične stanice jajnika.
Cancer stem cells comprising Lgr5 and/or 6 embedded in their cell membrane. 
Izolirane matične stanice karcinoma naznačene time da sadrže Lgr5 ugrađen u njihovoj staničnoj membrani.
Use of an Lgr5 or 6 binding compound in the preparation of a diagnostic for the diagnosis of cancer stem cell presence and/or content in a sample. 
Antitijelo, njegov derivat ili fragment koje ima afinitet za Lgr5, ili inhibitor transkripta Lgr5 mRNA, naznačeno time da je za uporabu kod in vivo dijagnoze prisutnosti i/ili udjela matičnih stanica karcinoma u tumoru.